Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer

Trial Profile

An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Goserelin (Primary)
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LARES
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Nov 2018 Planned End Date changed from 10 Jun 2020 to 31 Dec 2020.
    • 30 Nov 2018 Planned primary completion date changed from 10 Jun 2020 to 31 Dec 2020.
    • 30 Nov 2018 Planned initiation date changed from 5 Nov 2018 to 30 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top